USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: California Biotechnology, Inc.
Address: 2450 Bayshore Parkway
Mountain View, CA 94043
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,497,982.00 30
SBIR Phase II $4,657,450.00 10

Award List:

THE GOAL OF THE PROPOSED RESEARCH IS TO PRODUCE EFFECTIVE HUMAN PARATHYROID HORMONE (PTH) ANTAGONIST PEPTIDES IN ESCHERICHIA COLI USING STATE-OF-THE-ART RECOMBINANT DNA (RDNA) TECHNOLOGIES.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: George phillip vlasuk , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The goal of the proposed research is to produce effective human parathyroid hormone (pth) antagonist peptides in escherichia coli using state-of-the-art recombinant dna (rdna) technologies. the clinical utility of an effective antagonist to pth action in vivo lies in the treatment of hypercalcemic… More

TWO PEPTIDES WITH POTENT ANTI-HERPES ACTIVITY IN VITRO, MCP-1 AND MCP-2, HAVE BEEN ISOLATED FROM RABBIT MACROPHAGES.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Karen talmadge , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Two peptides with potent anti-herpes activity in vitro, mcp-1 and mcp-2, have been isolated from rabbit macrophages. the long-term objective of this application is the development of these peptides for human therapeutic use. because the natural source is limited, recombinant dna techniques will be… More

HYPERTENSION, RESULTING IN SECONDARY ORGAN DAMAGE AND REDUCED LIFE SPAN, IS ONE OF THE MOST IMPORTANT PUBLIC HEALTH PROBLEMS IN DEVELOPED COUNTRIES.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philippe m. frossard , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Hypertension, resulting in secondary organ damage and reduced life span, is one of the most important public health problems in developed countries. it is a multifactorial disease for which etiology is unknown in 95% of cases. there is currently no predictive diagnosis for this disease. the… More

THE RECENT DISCOVERY OF ATRIAL NATRIURETIC FACTOR (ANF) PEPTIDES IN MAMMALIAN ATRIA THAT HAVE POTENT NATRIURETIC, DIURETIC AND VASORELAXANT ACTIVITY HAS IMPLICATED THESE SUBSTANCES IN THE CONTROL OF FLUID VOLUME AND BLOOD PRESSURE.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert m. scarborough , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The recent discovery of atrial natriuretic factor (anf) peptides in mammalian atria that have potent natriuretic, diuretic and vasorelaxant activity has implicated these substances in the control of fluid volume and blood pressure. the proposed research will provide relevant structure-activity data… More

THE AIM OF THIS PROJECT IS TO DEVELOP CLONING VECTORS THAT DIRECT THE HIGH-LEVEL SYNTHESIS AND SECRETION OF HETEROLOGOUS PROTEIN PRODUCTS IN THE YEAST SACCHAROMYCES CEREVISIAE.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Judith abraham , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The aim of this project is to develop cloning vectors that direct the high-level synthesis and secretion of heterologous protein products in the yeast saccharomyces cerevisiae. a critical component needed for such vectors is a dna sequence coding for a secretion signal recognized by yeast. the gene… More

RECENTLY, SUBSTANCES WITH INTRINSIC NATRIURETIC, DIURETIC AND VASORELAXANT ACTIVITY HAVE BEEN ISOLATED FROM THE ATRIUM OF THE HEART.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: John a. lewicki , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Recently, substances with intrinsic natriuretic, diuretic and vasorelaxant activity have been isolated from the atrium of the heart. studies of these substances, termed atrial natriuretic factors (anf), have provided new information relevant to our understanding of the regulation of blood pressure… More

ATRIAL NATRIURETIC FACTOR (ANF) IS INVOLVED IN CONTROLLING BLOOD PRESSURE AND SALT BALANCE.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: John c. fiddes , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Atrial natriuretic factor (anf) is involved in controlling blood pressure and salt balance. the factors which regulate the expression of the anf gene will be studied. rats will be treated with agents that are known to affect blood pressure and extracellular fluid volume, e.g., high salt diet,… More

EXPRESSION OF HUMAN RENIN FROM CLONED GENES

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lawrence C. Fritz , Principal Investigator
Award Amount: $50,000.00

ENDOGENOUS ANTI-INFLAMMATORY PROTEIN: BIOLOGICAL TESTING

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lorin K. Johnson , Principal Investigator
Award Amount: $50,000.00

HUMAN LUNG SURFACTANT DEFICIENCY^DIAGNOSIS AND THERAPY

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Barbara Cordell , Principal Investigator
Award Amount: $50,000.00

HUMAN LUNG SURFACTANT DEFICIENCY^DIAGNOSIS AND THERAPY

Award Year / Program / Phase: 1986 / SBIR / Phase II
Agency: HHS
Principal Investigator: Barbara Cordell , Principal Investigator
Award Amount: $405,000.00
Abstract:
This proposal describes the development of a modern diagnostic test and therapy for infant respiratory distress syndrome (rds). rds is the leading cause of neonate mortality and morbidity. it is due to inadequate levels of lung surfactant, a lipid-protein complex essential for lung inflation.… More

EXPRESSION OF HUMAN RENIN FROM CLONED GENES

Award Year / Program / Phase: 1986 / SBIR / Phase II
Agency: HHS
Principal Investigator: Lawrence C. Fritz , Principal Investigator
Award Amount: $389,000.00
Abstract:
Hypertension is a serious and widespread medical problem. while a variety of approaches currently exist for controlling hypertension, many patients could benefit from new antihypertensive drugs that are more specific than those presently available. renin inhibitors constitute a potential class of… More

ENDOGENOUS ANTI-INFLAMMATORY PROTEIN: BIOLOGICAL TESTING

Award Year / Program / Phase: 1986 / SBIR / Phase II
Agency: HHS
Principal Investigator: Lorin K. Johnson , Principal Investigator
Award Amount: $500,000.00
Abstract:
Inflammatory disorders account for a significant percentage of debilitating diseases. it is now apparent that central to the therapeutic control of the inflammatory reaction is the regulation of the phospholipid metabolites, the eicosanoids. in most tissues the synthesis of the eicosanoids is… More

RESEARCHERS WILL DESCRIBE STUDIES DESIGNED TO DEVELOP SPECIFIC DIAGNOSTIC ASSAYS OF ATRIAL NATRIURETIC FACTOR AND ITS METABOLITES.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dale b schenk , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Researchers will describe studies designed to develop specific diagnostic assays of atrial natriuretic factor and its metabolites. such assays are currently not available but are required for a complete understanding of atrial natriuretic factor in the regulation of blood pressure. this study… More

THE GOAL OF THIS RESEARCH IS THE DEVELOPMENT OF RECOMBINANT CONTRACEPTIVE VACCINES, USING HUMAN CHORIONIC GONADOTROPIN (HCG) CARBOXY-TERMINAL PEPTIDE (CTP) AS A MODEL SYSTEM.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dr karen d talmadge , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The goal of this research is the development of recombinant contraceptive vaccines, using human chorionic gonadotropin (hcg) carboxy-terminal peptide (ctp) as a model system. to overcome current conjugation problems, genes encoding con- jugated hcg ctp fused poly-proteins can be synthesized. to… More

THE GOAL OF THIS RESEARCH IS TO PRODUCE EFFECTIVE STABLE MICROEMULSIONS OF LIPOSOLUBLE VITAMINS FOR INTRAVENOUS DELIVERY.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jean-louis vigne , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The goal of this research is to produce effective stable microemulsions of liposoluble vitamins for intravenous delivery. the administration of fat-soluble vitamins becomes a medical problem when deficiencies in these substances are displayed by subjects with malabsorption syndrome. liposoluble… More

ACCELERATED WOUND HEALING WITH FIBROBLAST GROWTH FACTOR

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: John C Fiddes , Principal Investigator
Award Amount: $50,000.00

PURIFICATION OF AN AUTOCRINE ANGIOGENESIS INHIBITOR

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark a snyder phd
Award Amount: $50,000.00
Abstract:
A protein has been identified from a cultured cell line which inhibits the growth of capillary endothelial cells in vitro. this protein will be purified from conditioned growth medium and used in in vitro and in vivo model systemsto test its ability to inhibit the formation of new capillaries. this… More

EXPRESSION VECTORS FOR SECRETED HUMAN ESTROGEN RECEPTOR

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Phyllis a ponte phd
Award Amount: $50,000.00
Abstract:
The long-term goal of the research is to obtain a chinese hamster ovary cell line capable of producing human estrogen receptor as a significant amount of its secreted protein. purified receptor protein may then be used (1) to obtain x-ray crystallographic data on the structure of the receptor to aid… More

FORMULATION OF RECOMBINANT HUMAN LUNG SURFACTANT

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: R. Tyler White Phd
Award Amount: $50,000.00

ANGIOGENESIS WITH ANTAGONIST AND AGONIST ANALOGS OF BASIC FGF

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrew A Protter Phd
Award Amount: $50,000.00

ACCELERATED WOUND HEALING WITH FIBROBLAST GROWTH FACTOR

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency: HHS
Principal Investigator: John C Fiddes , Principal Investigator
Award Amount: $500,000.00
Abstract:
Basic and acidic fibroblast growth factors (fgf) are two primary mitogens for capillary endothelial cells. bovine basic fgf, isolated from pituitaries, will be used in rat wound healing models to determine whether this factor can accelerate the rate of wound healing through promoting angiogenesis.… More

FORMULATION OF RECOMBINANT HUMAN LUNG SURFACTANT

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency: HHS
Principal Investigator: R. Tyler White Phd
Award Amount: $500,000.00
Abstract:
The objective of the proposed research is formulation of an effective synthetic surfactant to be used in treatment of infant respiratory distress syndrome (rds). rds is caused by inadequate levels of lung surfactant at birth, and is presently treated by assisting the newborn with mechanical… More

THE PREPARATION OF NOVEL MEMBRANE PERMEATION ENHANCERS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The long-term objective of the research proposed in this sbir grant application is to develop a transmucosal deliverytechnology which will eliminate the necessity for the parenteral administration of protein and peptide drugs. thegoals of the phase i program are to synthesize, physically… More

POTENTIAL BIOCHEMICAL DIAGNOSTIC FOR ALZHEIMER'S DISEASE

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
Alzheimer's disease is a growing medical problem afflicting 5% of the over-65 population in the us. despite its prevalence, neither positive diagnoses nor efficacious treatment exist. definitive diagnosis is made on autopsy using the histopathological hallmarks of the disease - fibrillar amyloid… More

ANGIOGENESIS WITH ANTAGONIST AND AGONIST ANALOGS OF BASIC FGF

Award Year / Program / Phase: 1989 / SBIR / Phase II
Agency: HHS
Principal Investigator: Andrew A Protter Phd
Award Amount: $494,000.00
Abstract:
Basic fibroblast growth factor (bfgf) is a potent mitogen and angiogenesis-promoting factor. analogs of bfgf will be synthesized by in vitro mutagenesis of a dna fragment codingfor human bfgf. the mutated bfgf-coding dna fragment will be engineered into a bacterial expression vector and transfected… More

ANTIBODIES TO ATRIAL PEPTIDE RECEPTOR

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $49,992.00

INHIBITORS OF ATRIAL NATRIURETIC PEPTIDE CLEARANCE

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

ANTIBODIES TO ATRIAL PEPTIDE RECEPTOR

Award Year / Program / Phase: 1990 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $490,968.00
Abstract:
Atrial natriuretic peptide (anp) binds to multiple cell surface receptors in a number of different tissues, resulting in effects related to cardiovascular homeostasis. this research involves the generation of specific antibodiesto a cloned anp receptor that appears to function in the metabolic… More

AN IN VITRO SCREEN FOR ATYPICAL BETA-ADRENERGIC AGONISTS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: R Tyler White
Award Amount: $50,000.00
Abstract:
The ultimate goal of this research is to develop a therapy for obesity based upon the identification of novel beta-adrenergic agonists that are selective stimulators of thermogenesis in humans. atypical (non-beta1, beta2) beta-adrenergic receptors (beta-ars) are thought to mediate sympathetic… More

A NEW ENDOTHELIAL CELL GROWTH FACTOR FOR WOUND HEALING

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Judith A Abraham
Award Amount: $50,000.00
Abstract:
Vascular endothelial cell growth factor (vegf) is a potent mitogen, secreted by bovine pituitary folliculo-stellate cells, that appears to be specific for vascular endothelial cells. this specificity suggests that vegf may be an ideal human therapeutic agent for indications where… More

AFFINITY MATRICES FOR PROCESS SCALE PURIFICATION

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paula J Shadle
Award Amount: $49,790.00
Abstract:
The aim of this research is to investigate the use of new affinity matrices in purification and cleavage of recombinant proteins at process scale. the performance of different affinity matrices for immobilization of enzymeswill be directly compared. scalability and performance willbe evaluated in… More

STRUCTURE AND FUNCTION OF ALZHEIMER'S DISEASE PROTEASE INHIBITOR

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Barbara Cordell
Award Amount: $50,000.00

INHIBITORS OF ATRIAL NATRIURETIC PEPTIDE CLEARANCE

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $467,104.00
Abstract:
The atrial natriuretic peptide (anp) hormonal system, which has an important biological role in fluid and electrolyte homeostasis, represents an important new therapeutic target for cardiovascular disease states. this research is based on the recent identification of a novel mechanism for clearance… More

MOLECULAR CLONING OF CDNA ENCODING OXIDIZED LDL RECEPTOR

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Endemann, Gerda C , Principal Investigator
Award Amount: $48,200.00
Abstract:
The long term objective of this research is to develop drugs to prevent progression/formation of atherosclerotic lesions in humans. lipid deposition in the arterial wall has been shown in animal models to involve the initial accumulation of lipid by macrophages. evidence to date suggests that this… More

ISOLATION OF INSULIN RECEPTOR PHOSPHATASES

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sweet, Laurel J , Principal Investigator
Award Amount: $50,000.00
Abstract:
The ultimate objective of this research is to develop a novel treatment for diabetes based on the enhancement of insulin action through the inhibition of an insulin receptor-specific phosphotyrosine phosphatase (ptpase). phosphorylation of the insulin receptor beta-subunit, in response to insuli… More

RECOMBINANT CNTF FOR TREATMENT OF NEUROPATHIES

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Barbara Cordell , Principal Investigator
Award Amount: $50,000.00
Abstract:
Ciliary neurotrophic factor (cntf) is a potent polypeptide hormone whose actions appear to be restricted to the nervous system. cntf has been observed to promote survival, neurotransmitter synthesis and neurite outgrowth in various sympathetic, sensory and parasympa- thetic neurons at femtomolar to… More

WOUND REPAIR WITH HEPARIN-BINDING EGF-LIKE GROWTH FACTOR

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Abraham, Judith A , Principal Investigator
Award Amount: $50,000.00

STRUCTURE AND FUNCTION OF ALZHEIMER'S DISEASE PROTEASE INHIBITOR

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Barbara Cordell
Award Amount: $496,634.00
Abstract:
Approximately 5 percent of the population over age 65 in theunited states suffers from alzheimer's disease (ad). despite its prevalence, no efficacious treatments exist. definitive diagnosis is made on autopsy using the histopathological hallmark of the disease-amyloid depositionin the brain and… More

WOUND REPAIR WITH HEPARIN-BINDING EGF-LIKE GROWTH FACTOR

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Abraham, Judith A , Principal Investigator
Award Amount: $414,744.00
Abstract:
Using heparin affinity chromatography, a novel fibroblast and vascular smooth muscle cell mitogen has been isolated from the conditioned medium of the human histiocytic lymphoma cell line u-937. analysis of cdna clones has shown that this factor is a new member of the egf/tgfalpha family of… More